-
EHA China Spotlight | Professor Jing Pan: Previous-Transplant or New-Match Donor CD5 CAR-T Cells in Pediatric and Adult Relapsed/Refractory T-ALL
CAR-T cell therapy is rapidly advancing in the field of hematologic malignancies, including significant progress in the treatment of T-cell lymphomas. However, challenges such as relapse, off-target effects, and viral infections still need to be addressed to further optimize the effectiveness of CAR-T cell therapy. At the recent 2024 European Hematology Association (EHA) Annual Meeting,…
-
Professor Xiaofan Zhu’s In-depth Analysis of EHA Selected Research on Pediatric MDS
Pediatric Myelodysplastic Syndromes (MDS) are rare hematologic disorders, with advanced MDS being particularly concerning. At the 29th Annual Meeting of the European Hematology Association (EHA 2024), Professor Xiaofan Zhu’s team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences presented multiple studies, including two key studies on pediatric MDS. These…
-
Results of the Phase II CHESS Study on Zanubrutinib Combined with Rituximab Sequential Short-Course R-DHAOx Regimen
Mantle cell lymphoma (MCL) is a medium- or small-B-cell lymphoma originating from the mantle zone of lymph node follicles, accounting for about 4.6% of B-cell non-Hodgkin lymphomas (NHL). The median age of onset for MCL is 65 years, with a higher incidence in males, with a male-to-female ratio of approximately 2-4:1. MCL can be categorized…
-
EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical…
-
Professor Enqiang Chen: Identification and Management of Cholestatic Drug-Induced Liver Injury Related to Antitumor Drugs
Cholestatic drug-induced liver injury (DILI) is a drug-induced condition characterized primarily or prominently by intrahepatic cholestasis, featuring clinical, biochemical, and histopathological evidence. It is a relatively common and serious adverse drug reaction that can lead to acute liver failure and even death, affecting the clinical application of medications. In recent years, significant breakthroughs in targeted…
-
ASCO 2024丨New Research Highlights on Cholangiocarcinoma: Mixed Results for Targeted and Immunotherapy
Cholangiocarcinoma (BTC), often called the “silent killer,” constitutes less than 1% of adult cancers and has a poor prognosis with limited patient survival. Current treatments primarily involve surgery and chemotherapy, but their efficacy is limited. Recently, various targeted drugs and immune checkpoint inhibitors (ICIs) have provided new therapeutic options for BTC patients. The 2024 American…
-
Xinghai Forum: I CAME, I SAW, I-SPY—Exploring the Highlights of the I-SPY 2.2 Study and Its Clinical Practice Value
From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was grandly held, bringing together cutting-edge developments from home and abroad. At the previous ASCO conference, the results of the I-SPY 2.2 study were released, providing new insights into optimizing neoadjuvant treatment plans for breast cancer, exploring the application…
-
EHA China’s Voice : Professor Jia Wei’s Team on UBE2Q1’s Impact on Antigen Presentation in AML and Clinical Prognosis and Molecular Characteristics
The 29th Annual Congress of the European Hematology Association (EHA) was held grandly in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific…
Connecting Medical Expertise through Media